Quotables
"There is no reason anyone would want a computer in their home."
Ken Olsen, chairman and founder of Digital Equipment Corporation ; 1977
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8039620 | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate Crystalline forms of Varenicline Tosylate: are provided, along with processes for preparing those crystalline forms of Varenicline Tosylate, and processes for obtaining high purity Varenicline base using Varenicline Tosylat... | 10/18/2011 |
| 7435735 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4... | 10/14/2008 |
| 7427445 | Compound capable of being used in organic layer of organic light emitting device Disclosed is a compound represented by the following formula 1 as a light emitting material: wherein each of R0, R1 and R2 is the same as defined herein. An organic light emitting device including a first electro... | 09/23/2008 |
| 7326475 | Material for organic electroluminescent device, organic electroluminescent device, illuminating device and display The present invention provides: an organic EL element exhibiting high luminance, a high external quantum efficiency and a long high temperature driving life at 50° C.; an illuminator and a display device employing the organic EL element; and a material preferably u... | 02/05/2008 |
| 7288648 | High temperature crystallization of 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903,11]-dodecane A method of crystallizing an epsilon-polymorph of 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903,11]-dodecane (CL-20). The method comprises combining the CL-20, at least one organic solvent, and at least one nonsolvent to ... | 10/30/2007 |
| 7273869 | Inhibitors of Akt activity The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this inven... | 09/25/2007 |
| 7253292 | Synthesis of cyclopentadiene derivatives A process for preparing cyclopentadiene derivatives comprising the steps of: a) coupling a five membered heterocycle ring with a five or six membered heterocycle ring; b) reacting the obtained compound with a carbonilating system: c) reducing the obtained compound. | 08/07/2007 |
| 7135468 | Antibacterial compounds Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, salts of prodrugs, and metabolites thereof, processes for making the compounds and intermediates in the processes, composit... | 11/14/2006 |
| 7049437 | Synthetic process and crystal form of condensed imidazopyridine derivatives The present invention provides a process of a compound of the formula (I): wherein R is heteroaryl or the like, ring A is a heteroalicyclic group or the like comprising reacting a compound of the formula (II): | 05/23/2006 |
| 7045660 | Compounds as PDE IV and TNF-inhibitors This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment... | 05/16/2006 |
| 7008941 | Reverse-turn mimetics and methods relating thereto Conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins having the following structure are disclosed: wherein A, B, X, R1 | 03/07/2006 |
| 6992185 | Crystallization of 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903,11]-dodecane A method is provided in which 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903,11]-dodecane (CL-20 or HNIW) is crystallized to its ε-polymorph by an inverse precipitation technique. A dry CL-20 solvent solution containing a... | 01/31/2006 |
| 6962936 | Triazole-derived kinase inhibitors and uses thereof Described herein are compounds that are useful as protein kinase inhibitors having the formula: where Ht, R2, T, and m are as described in the specification. The compounds are useful... | 11/08/2005 |
| 6960587 | Condensed pyrazindione derivatives as PDE inhibitors Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as therapeutic agents. ... | 11/01/2005 |
| 6930109 | Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disor... | 08/16/2005 |
| 6927214 | Non-peptide GLP-1 agonists Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of... | 08/09/2005 |
| 6911445 | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder... | 06/28/2005 |
| 6861427 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists Compounds of the formula are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia, and are also useful for the treatmen... | 03/01/2005 |
| 6858607 | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof The present invention is directed to substituted 4H-chromene and analogs thereof, represented by the general Formula I: or pharmaceutically acceptable salts or prodrugs thereof, wherein: wherein A, R1 | 02/22/2005 |
| 6703391 | Quinoxalinedione derivatives, their preparation and use A compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R1 is hydrogen, alkyl, arylalkyl, (CH2)n OH, or (CH2)n NR7 | 03/09/2004 |
| 6703401 | Compounds, their preparation and use The present invention relates to compounds of the general formula (I) ##STR1## The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).... | 03/09/2004 |
| 6673798 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same A purified tyrphostin of a general formula: ##STR1## wherein, for Compound I, R6 is either at position 6 or at position 7, or, for Compound II, R6 is either at position 6 or at position 8.... | 01/06/2004 |
| 6656940 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein ty... | 12/02/2003 |
| 6635759 | Luminescent 4-trifluoromethyl 1-2-quinolones with long wave UV absorption and the use thereof The invention relates to a substituted 4-trifluoromethyl carbostyril according to formula (I) and is characterised in that the 4-trifluoromethyl carbostyril is provided with an absorption maximum between 350 and 420 nm and a luminescence maximum between 4... | 10/21/2003 |
| 6617327 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline Compounds of the formula: ##STR1## are useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesit... | 09/09/2003 |
| 6608194 | Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them A compound of Formula (Ih) ##STR1## The compounds may be used, inter alia, for preparing beta aryl-alpha-oxy substituted alkylcarboxylic acids.... | 08/19/2003 |
| 6602875 | Sorbitol dehydrogenase inhibitors This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, ##STR1## wherein R1, R2 and R3 are as defined in the specification. This invention is also directed to pharmaceutical compositions... | 08/05/2003 |
| 6525181 | Cyanine dyes The object of the present invention is to provide organic dye compounds which exert satisfactory optical absorption properties and thermal resistance when used in high density optical recording media. The above object is solved by specific trimethine cyan... | 02/25/2003 |
| 6518423 | Benzopiperidine derivatives Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: ##STR1## wherein the variables are as described in the specification. These compounds are useful as ... | 02/11/2003 |
| 6462038 | Androgen receptor modulator compounds and methods Compounds, pharmaceutical compositions, and methods for modulating processes mediated by steroid receptors. In particular, preparation and methods of use of non-steroidal compounds and compositions that are agonists, partial agonists, and antagonists for ... | 10/08/2002 |
| 6416601 | Method of recovery for nitramines from aluminized energetic materials Nitramines are one of the more expensive and often the more plentiful ingredients found in energetic materials, such as solid rocket motor propellants, explosives, and pyrotechnics. By treating aluminized energetic material with an aqueous nitric acid sol... | 07/09/2002 |
| 6380235 | Benzimidazolones and analogues The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula: ##STR1## wherein: A is O, S, or NR4 ; B is a bond between A and C.dbd.Q, or the mo... | 04/30/2002 |
| 6365586 | Compounds, their preparation and use The present invention relates to compounds of the general formula (I) ##STR1## The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).... | 04/02/2002 |
| 6358954 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same An isometric enriched tyrphostin of a general formula: ##STR1## wherein, for Compound I, the tyrphostin is enriched either for R6 at position 6 or for R6 at position 7, or, for Compound II, the tyrphostin is enriched either for R | 03/19/2002 |
| 6355783 | Compounds for mass coloration of high temperature polymers The invention relates to novel soluble pigment precursors possessing not only higher thermal stability but also improved solubility characteristics and to a process for mass coloration of high temperature polymers that utilizes these novel soluble pigment... | 03/12/2002 |
| 6329375 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein ty... | 12/11/2001 |
| 6221867 | 4,5-pyrazinoxindoles Disclosed are novel 4,5-pyrazinoxindoles having the formula ##STR1## These compounds inhibit or modulate protein kinases, in particular JNK protein kinases. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are u... | 04/24/2001 |
| 6197771 | Glutamate (ampa/kainate) receptor antagonists: N-substituted fused azacycloalkylquinoxalinediones Novel N-substituted azacycloalkyl ring fused 2,3-quinoxalinediones represented by the formula: ##STR1## or a pharmaceutically acceptable salt thereof, are disclosed, wherein the formula variables R1, R2, X, Y, m and n are as defined ... | 03/06/2001 |
| 6168838 | Fluorinated phenantrene derivatives for liquid crystal mixtures Fluorinated phenanthrene derivatives and their use in liquid-crystalline mixtures Fluorinated phenanthrene derivatives of the formula (I) ##STR1## in which G is --CHF--CH2 -- or --CF.dbd.CH--, E1, E2, E3, E4 | 01/02/2001 |
| 6127368 | Anellated ଲ-carbolines Compounds of formula I ##STR1## are described, as well as the process for their production and their use in pharmaceutical agents.... | 10/03/2000 |
